JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

Search

CareDx Inc

Open

SectorGezondheidszorg

20.6 0.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.79

Max

20.75

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

16.25

90.422

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-12.54% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

321M

1.1B

Vorige openingsprijs

20.16

Vorige sluitingsprijs

20.6

Nieuwssentiment

By Acuity

50%

50%

133 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 jan 2026, 23:51 UTC

Winsten

Correction to Samsung Fourth-Quarter Net Profit Article

28 jan 2026, 23:49 UTC

Populaire aandelen

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 jan 2026, 23:19 UTC

Winsten

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 jan 2026, 22:43 UTC

Winsten

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 jan 2026, 00:00 UTC

Acquisities, Fusies, Overnames

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 jan 2026, 00:00 UTC

Acquisities, Fusies, Overnames

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 jan 2026, 00:00 UTC

Acquisities, Fusies, Overnames

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 jan 2026, 00:00 UTC

Acquisities, Fusies, Overnames

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 jan 2026, 23:49 UTC

Marktinformatie

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 jan 2026, 23:30 UTC

Marktinformatie

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 jan 2026, 23:28 UTC

Winsten

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 jan 2026, 23:26 UTC

Winsten

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 jan 2026, 23:21 UTC

Winsten

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 jan 2026, 23:18 UTC

Winsten
Acquisities, Fusies, Overnames

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 jan 2026, 22:58 UTC

Winsten

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 jan 2026, 22:48 UTC

Marktinformatie

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 jan 2026, 22:45 UTC

Winsten

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 jan 2026, 22:44 UTC

Winsten

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 jan 2026, 22:43 UTC

Winsten

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 jan 2026, 22:41 UTC

Winsten
Populaire aandelen

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 jan 2026, 22:41 UTC

Marktinformatie

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 jan 2026, 22:41 UTC

Winsten

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 jan 2026, 22:40 UTC

Winsten

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 jan 2026, 22:39 UTC

Winsten

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 jan 2026, 22:38 UTC

Winsten

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 jan 2026, 22:37 UTC

Winsten

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 jan 2026, 22:35 UTC

Winsten

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 jan 2026, 22:26 UTC

Marktinformatie
Winsten

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 jan 2026, 22:20 UTC

Marktinformatie

Global Equities Roundup: Market Talk

28 jan 2026, 22:20 UTC

Marktinformatie

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-12.54% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -12.54%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

133 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat